



New Location Positions Modalis Therapeutics for Pre/Clinical Development and Future Growth

20-October-2021 TOKYO & Massachusetts.- Modalis Therapeutics Corporation (Modalis), a leading company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenetic gene modulation technology, announced today the relocation and expansion of its US corporate research facility to in Waltham, MA to advance its R&D operations and growth of the company.

"We are thrilled to be relocating our research lab to the Greater Boston area as the area will provide the foundation for our new growth initiatives going forward. Adjacent to Cambridge where top tier universities and pharma/biotech companies are located, Waltham is one of the top business growth areas in Massachusetts offering an educated, diverse, and growing population, making it an ideal location for Modalis' future," said Modalis President & CEO, Haru Morita. "Moving into this new space is further validation of our technology, products, people, and potential, and it will ensure the company is best positioned to continue developing the game changing products for unmet medical needs."

Expanding to 13,000 square feet in the Greater Boston area, the location is substantially upgraded from the Company's prior facility and will provide the necessary infrastructure for the Company to continue to build momentum.

According to Tetsuya Yamagata, SVP and CTO, "We plan to utilize the new corporate space to continue our research and development initiatives and accelerate preclinical, regulatory, and manufacturing that will advance cutting edge technology and pipelines. The mission of Modalis is to shed light on rare disorders and deliver therapeutics for unmet medical needs. We are advancing gene therapies with CRISPR-GNDM® that will make a difference in the lives of individuals suffering from genetic disorders."

About Modalis:

Modalis Therapeutics is developing precision genetic medicines through epigenetic gene modulation. Modalis is pursuing therapies for orphan genetic diseases using its proprietary CRISPR-GNDM technology which enables the locus specific modulation of gene expression or histone modification without the need for double-stranded DNA cleavage, gene editing or base editing. Modalis is focusing initially on genetic disorders caused by loss of gene regulation – resulting in excess or insufficient protein production – which includes more than 660 genes that are currently estimated to cause human disease due to haploinsufficiency. Headquartered in Tokyo with laboratories and facilities in Cambridge, Massachusetts. For additional information, visit www.modalistx.com.

Forward-Looking Statements:

This document has been prepared by Modalis Therapeutics corporation and Modalis Therapeutics Inc. (the "Companies") solely for information purpose only. This document does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Companies in Japan, the United States or any other jurisdictions. The information contained herein is based on current economic, regulatory, market trends and other conditions. The Companies make no representation or guarantee with respect to the credibility, accuracy or completeness of the information herein. The information contained herein may change without prior notice. You may not publish or use this document and the contents thereof for any other purpose without a prior written consent of the Companies. Furthermore, the information on future business results are forward-looking statements. Forward-looking statements include but not limited to expressions such as "*believe*", "*expect*", "*plan*", "*strategic*", "*expect*", "*anticipate*", "*predict*" and "*possibility*", as well as other similar expressions to explain future business activities, achievements, events and future conditions. Forward-looking statements are predictions about the future that reflect management's judgment based on currently available information. As such, these forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed in or suggested by the forward-looking statements. Therefore, you may not rely entirely on forward-looking statements. The Companies do not assume any obligation to change or correct any forward-looking statements in light of new information, future events or other findings. This document and its contents are confidential and are being provided to you solely for your information and may not be retransmitted. This presentation is being furnished to you solely for your information and may not be reproduced or redistributed to any other person. In giving this presentation, the Companies do not undertake any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. Information on companies other than the Companies and information provided from third parties are based on public information or sources. The Companies have not independently verified the accuracy and appropriateness of such data and indicators used herein, nor assume any responsibility for the accuracy and appropriateness of such data and indicators presented in this document.

Contacts

Modalis Therapeutics
Sawako Nakamura
media@modalistx.com